Rate Adaptive Pacing Research Articles

Adaptive Rate Pacing Controlled by Right Ventricular Preejection Interval for Severe Refractory Orthostatic Hypotension

A 72-year-old African-American man with frequent recurrent syncope was found to have severe refractory orthostatic hypotension with concomitant supine hypertension. Pharmacotherapy was successful in controlling his supine hypertension but was unable to resolve his severe orthostatic hypotension. Temporary fixed rate tachypacing was only minimally effective in preventing syncope during upright tilt, while variable rate pacing based on degree of blood pressure fall was far superior. Following these observations, an adaptive rate pacing system controlled by right ventricular preejection interval was implanted (Precept DR Model 1200). The system adequately sensed the patient's fall in blood pressure when sitting or standing and augmented its rate accordingly, thus preventing syncope. While supine, the pacing rate fell to 60 ppm, thereby, avoiding an exacerbation of his concomitant supine hypertension. Over a 3-month follow-up period, he has had no further orthostatic or syncopal episodes. We conclude that adaptive rate pacing using right ventricular preejection interval may be an effective treatment for severe refractory orthostatic hypotension.

Experience with an implantable tiered therapy device incorporating antitachycardia pacing and cardioverter/defibrillator therapy

The implantable cardioverter-defibrillator provides an alternative therapy for medically refractory ventricular tachyarrhythmias in patients who are not candidates for ventricular operations or in whom these operations have failed. Currently, however, available devices have limitations. In this report we describe our experience with a programmable, tiered therapy device with anti-ventricular tachyarrhythmia pacing and VVI pacing capabilities (Cadence V-100, Ventritex Inc., Sunnyvale, Calif.). This device offers certain advantages compared with conventional implantable cardioverter-defibrillators: (1) tiered, anti-ventricular tachyarrhythmia therapy incorporating programmable, rate-adaptive burst pacing in addition to energy-programmable cardioversion/defibrillation, (2) biphasic cardioversion/defibrillation waveforms, resulting in lower defibrillation thresholds, (3) the ability to abort therapy for nonsustained ventricular tachyarrhythmias, (4) electrogram storage of detected events for later retrieval and analysis, (5) noninvasive, device-generated programmed stimulation for system testing, and (6) backup VVI pacing capability. Forty patients (aged 14 to 79 years) with ventricular tachyarrhythmias refractory to medical therapy received this device. The mean left ventricular ejection fraction was 33% +/- 16%. Preoperative electrophysiologic testing revealed inducible monomorphic ventricular tachyarrhythmia responsive to rapid ventricular pacing in 36 patients (90%). An extrapericardial two-patch configuration was used with either epicardial screw-in or bipolar endocardial sensing/pacing wires. No operative mortality and no device-related infection occurred. During a follow-up period of 16 +/- 7 months (range 3 to 30 months), 38 patients remained active with the implanted device; one patient died of congestive heart failure 4 months after implantation, and the system was explanted in one patient who underwent cardiac transplantation. In 33 patients a total of 1815 ventricular tachyarrhythmias were detected that resulted in therapy. Rate-adaptive burst pacing was used as the initial therapy in 1470 episodes and was successful in 1352 instances (92%). Pacing-induced ventricular tachyarrhythmia acceleration occurred in 4% of episodes. The remaining ventricular tachyarrhythmia episodes were treated with cardioversion. In 18 patients (45%) cardioversion therapy was aborted after spontaneous termination of ventricular tachyarrhythmia.(ABSTRACT TRUNCATED AT 400 WORDS)

Late follow-up of dual-chamber rate-adaptive pacing

Dual-chamber pacing systems with sensor-based rate-adaptive capability (DDDR pacemakers) provide paced patients with the potential benefits of both a reliable chronotropic response and maintenance of atrioventricular (AV) synchrony. However, there is concern that clinical and programming complexities may necessitate frequent reprogramming of pacemakers from the DDDR mode to less physiologic pacing modes (in particular VVI or VVIR). Consequently, this study assessed the stability of pacing-mode programming, and the factors affecting pacing-mode selection in patients with a DDDR-capable pacing system. Clinical status during follow-up (18.2 ± 6.7 months) was assessed in 75 patients. Principal diagnoses providing an indication for pacing were: (1) AV block alone, 18 of 75 patients (24%); (2) sick sinus syndrome alone, 41 (55%); and (3) combined AV block and sick sinus syndrome, 16 (21%). Twenty-three patients had history of atrial tachyarrhythmias. At implantation, 66 devices (88%) were programmed to DDDR mode, 7 (9%) to DDD, and 2 (3%) to DVIR. At last follow-up, the respective distribution of programmed modes was 83% DDDR, 10% DDD, 4% DVIR and 3% VVIR. During the study, the initial pacing mode remained unchanged in 54 patients (72%) and needed modification in 21 (28%). Of the latter 21 patients, atrial tachycardia was the basis for a programming change in 11 (52%), of whom 8 had history of atrial tachycardias. In general, postimplant atrial arrhythmia occurrences proved controllable, and ultimately return to a rate-adaptive dualchamber pacing mode (DDDR, DDD or DVIR) was achieved in most cases. The remaining reprogrammings were primarily to optimize hemodynamic benefit. Consequently, although reprogramming may be needed (28% of patients in this study), especially in patients with history of atrial tachyarrhythmias, the flexibility provided by DDDR-capable pacing systems enabled maintenance of dual-chamber rate-adaptive pacing in most patients during follow-up.

Cardiac pacing and aviation.

Certain applicants with stable disturbances of rhythm or conduction requiring cardiac pacing, in whom no other disqualifying condition is present, may be considered fit for medical certification restricted to multi-crew operations. The reliability of modern pacing systems appears adequate to permit restricted certification even in pacemaker dependent subjects except for certain models of pacemakers and leads known to be at increased risk of failure. These are to be avoided. There is little evidence to suggest that newer devices are any more reliable than their predecessors. Single and dual chamber systems appear to have similar reliability up to 4 years, after which time significant attrition of dual chamber devices occurs, principally due to battery depletion. All devices require increased scrutiny as they approach their end of life as predicted from longevity data and pacing characteristics. Unipolar and bipolar leads are of similar reliability, apart from a number of specific bipolar polyurethane leads which have been identified. Atrial leads, particularly those without active fixation, are less secure than ventricular leads and applicants who are dependent on atrial sensing or pacing should be denied certification. Bipolar leads are to be preferred due to the lower risk of myopotential and exogenous EMI. Sensor-driven adaptive-rate pacing systems using active sensors may have reduced longevity and require close scrutiny. Activity-sensing devices using piezoelectric crystal sensors may be subject to significant rate rises in rotary wing aircraft. The impracticality of restricted certification in helicopters will, in any event, preclude certification. Such devices would best be avoided in hovercraft (air cushioned vehicle) pilots. Only minor rate rises are likely in fixed-wing aircraft which are unlikely to be of significance. Anti-tachycardia devices and implanted defibrillators are inconsistent with any form of certification to fly.

New Concept in Activity‐Controlled Pacemakers: Clinical Results With an Accelerometer‐Based Rate Adaptive Pacing System

An accelerometer-based rate adaptive generator (EXCEL VR) has been introduced. A preclinical group of 22 subjects with strap-on devices was observed and reported. A clinical protocol including observation of rate adaptive response to typical daily activities and incremental exercise on a treadmill was administered in seven implanted patients. Indications for implantation in these patients was either second- or third-degree atrioventricular block (five patients, VVIR pacing mode) and sick sinus syndrome (two patients, AAIR pacing mode). Mean pacing rates were 50 ppm (supine), 56 ppm (standing), 77 ppm (descending the stairs), 81 ppm (slow walk), 83 ppm (slow stair climb), 91 ppm (fast walk), and 92 ppm (fast stair climb). When the arm proximal to the pulse generator was exercised, the rate rose to 92 ppm. When the distal arm was strained, the rate was 63 ppm. During treadmill testing, rates between 82 ppm (2 km/hour) and 104 ppm (5 km/hour) were observed. This accelerometer-based rate adaptive pulse generator provided a proportional response to graded activities of treadmill exercise and daily living in these groups of preclinical and clinical subjects.

Right ventricular conductance to establish closed-loop pacing.

Innovations in pacing technology, which include the addition of rate-responsive features to programmable pacemakers, can improve the quality of life of patients suffering from sick sinus syndrome. Among the strategies providing rate-adaptive cardiac pacing, the most attractive is the physiological restoration of closed-loop chronotropic control. This paper describes how autonomic nervous system (ANS) control information is extracted from dynamic measures of myocardial contractile performance obtained from unipolar conductance measurements using the stimulation electrode in the right ventricular cavity. The pacemaker uses the ANS information to modulate pacing rate and restore normal physiological control of heart rate. A new algorithm, regional effective slope quantity (RQ), for isolating the ANS signal was developed. The resulting signal, ventricular inotropic parameter (VIP), is a normalized parameter proportional to the strength of the ANS inotropic signals to the myocardium. The efficacy of the ANS control concept was evaluated in multi-centre studies. Patients with AV block and VIP-controlled pulse generators performed defined exercise protocols. The ANS-controlled pacing rate and the spontaneous sinus rate were closely correlated. Blood pressure and subjective patient reports further indicated that good control of the cardiovascular circulation was achieved.

Initial clinical experience with a single pass VDDR pacing system.

Although ventricular rate adaptive pacing (VVIR) improves exercise capacity and cardiac output compared to constant rate ventricular pacing (VVI), this pacing mode does not provide benefit of atrioventricular (AV) synchrony. We evaluated the use of a custom-built VDDR pacing system using a single pass, ventricular lead, which detects endocavity P wave using a pair of diagonally arranged atrial bipolar (DAB) electrodes. In the VDDR mode, AV synchrony is enabled and the P wave rate is used in conjunction with an accelerometer based activity sensor for rate adaptive pacing. A VDDR pacemaker was implanted in three patients with complete AV block (mean age 63 +/- 1 year) and the mean implantation time was 29 minutes. Mean P wave amplitude was 2.4 mV (1.2-4.2 mV) at implantation and telemetered P wave amplitude was stable over a follow-up of 6 months. At a sensitivity of 0.2 mV, stable P wave sensing was observed during breathing maneuvers, arm swinging, myopotential induction, and Holter recording. Paired exercise tests performed in the VDDR and VVIR modes showed higher cardiac output at rest, during exercise, and in the recovery period in the VDDR pacing mode. Thus VDDR pacing using a single pass lead is superior to VVIR pacing by enabling P synchronous ventricular pacing without adding to the complexity of implantation.

Comparison of Two Activity-Controlled Rate-Adaptive Pacing Principles: Acceleration versus Vibration

Activity-guided rate-adaptive pacing is currently the most widely used principle for rate adaptation. Broad experience has been gathered from several hundred thousand pacemakers that adjust the pacing rate according to vibrational forces detected by a piezosensor bonded to the inner side of the pacemaker can. A new generation of accelerometer-based pacemakers has been introduced into clinical practice. The vibrational type detects vibration, pressure, and shock waves traveling through the body with physical stress and using the pacemaker can as a resonator. In contrast, the accelerometer is insulated from the pacemaker housing and is incorporated into electronic hybrid circuitry. The forces detected by an accelerometer are motion and acceleration of the body in an anterior-posterior direction. Clinical studies conducted to date have shown that the accelerometer to be superior to the conventional vibration activity pacemakers, as far as the discrimination of different workloads and rejection of unwanted environmental noise are concerned.

Follow-up of a minute ventilation rate adaptive pacemaker.

Although rate adaptive pacemakers are now frequently prescribed, there is limited information regarding long-term follow-up of patients with a pacemaker capable of rate adaptation. We have examined our patients in whom a pacemaker capable of rate adaptation via a sensor that determines minute ventilation has been implanted. After following a group of 42 patients for a mean of 13.2 months we have found this to be a reliable rate adaptive pacing system. The sensor was reliable long term, the system is easy to program, and sensor settings were changed infrequently.

Adaptive-Rate Pacemakers: Comparison of Sensors and Clinical Experience

Many types of artificial sensors for adaptive-rate pacing have appeared but as yet there is no single sensor that properly reflects metabolic demand under all circumstances. Several other types of sensors are currently evaluated. Combinations of different sensors in a single unit are very promising. At present, however, the only completely satisfactory sensor is the normal sinus node.

The range of sensors and algorithms used in rate adaptive cardiac pacing.

Implantable sensors play an important role in physiological cardiac pacing. Sensors can be classified according to the technical methods in which sensing is achieved: the sensing of the evoked ventricular response, intrathoracic impedance and body acceleration forces, and the incorporation of special sensors on pacing electrodes. These sensors differ in their relative merits in terms of speed, proportionality, sensitivity, and specificity of rate response. The efficacy of a sensor can be significantly modified by the algorithm used in relating sensor signal to a pacing rate change. The currently available types of sensors and algorithms are summarized and compared in this review article. The relative merits of these sensors and algorithms form the basis for designing a multisensor pacing system.

Advantages of Dual Chamber Rate Adaptive Pacing Compared With Ventricular Rate Adaptive Pacing in Patients With Pulmonary Disease

Advantages of Dual Chamber Rate Adaptive Pacing Compared With Ventricular Rate Adaptive Pacing in Patients With Pulmonary Disease

Adaptive rate pacing controlled by the right ventricular preejection interval: clinical experience with a physiological pacing system.

In the Precept pacing system, the right ventricular intracardiac impedance waveform is used to evaluate either of two indicators of metabolic demand relative right ventricular stroke volume and preejection interval (PEI). PEI is known to reliably parallel contractility changes, which is reflective of physical and emotional stress. The stability and dynamic behavior of PEI were tested in ten patients with a Precept pacing system under various forms of exercise and during postural changes. Although significant patient-to-patient variability of the sensor values was observed, reflecting individual physiological differences, the chronic stability of PEI was excellent in the total device experience of 147 months. In all patients, PEI shortened significantly during bicycle ergometry from a mean value of 137.7 +/- 17.8 (range 96-162) to a mean value of 103.0 +/- 21.6 (range 92-109) (P less than 0.05). Low level bicycle exercise of short duration resulted in a prompt decrease in PEI and increase in pacing rate in all patients. There were no uniform postural responses overall, although some posture related rate changes were observed in two patients. We conclude that the first generation of a PEI based pacing system holds promise for adaptive rate pacing.

Postpericardiotomy syndrome complicating transvenous dual-chamber rate-adaptive pacing: Diagnosis aided by transesophageal echocardiography

Postpericardiotomy syndrome complicating transvenous dual-chamber rate-adaptive pacing: Diagnosis aided by transesophageal echocardiography

The Next 5 Years in Cardiac Pacemakers: A Preview

Advances in cardiac pacing continue at an astounding rate, and, occasionally, technologic capabilities are developed almost faster than they can be implemented clinically. The development and implementation of single- and dual-chamber rate-adaptive pacemakers have been the major thrusts in cardiac pacing in recent years. Rate-adaptive pacing will continue to be of primary interest in the future as investigators search for the perfect "sensor" and attempt to develop rate-adaptive pacemakers with multiple sensors. The "smart" pacemaker--that is, an autoprogramming, autodiagnostic device--will also be refined. The ultimate "smart" pacemaker would be capable of automatically adjusting output and sensing factors as well as altering the rate-adaptive variables and even changing the pacing mode in response to variations in the underlying rhythm. Other aspects of cardiac pacing that will be actively investigated include new low-threshold pacing lead designs, refinements of the single-lead pacing system capable of P-synchronous pacing, and diagnostic information that can be derived from sensors used for rate-adaptive pacing.

Pacemaker hemodynamics: Clinical implications

Our review of the current literature and experience in caring for pacemaker patients suggests that a consideration of hemodynamics is a logical way to approach pacemaker selection and programming. Multiple clinical factors enter into the selection of a pacemaker or pacemaker programming settings in each case. It appears that in patients with sinus node disease, atrial-inhibited or dual-chamber pacing provides the best chance for preventing the development of chronic atrial fibrillation with its attendant risks of embolism and stroke. It is clear that AV synchrony has beneficial hemodynamic effects at rest in most patients. The results of Labovitz would suggest that in patients with marked left atrial enlargement, this may be less so. 10 The results of Stewart et al would further suggest that in patients with retrograde VA conduction, dual-chamber pacing is preferable. 11 Retrograde VA conduction can be intermittent and this makes it difficult to use its absence on a single test to decide on the type of pacemaker to use. It appears that baseline left ventricular function does not determine the relative improvement in cardiac output observed with AV synchrony or rate-adaptive pacing. However, in patients with severe congestive heart failure even a small improvement in cardiac output may result in significant clinical improvement. Studies have shown that in any given patient, there may be an optimal AV interval at rest. In general, this ranges from 100 to 150 milliseconds. In normal individuals the optimal AV interval shortens with increased heart rate during exercise in a predictable and linear fashion. The hemodynamic benefits of a shortened AV interval with faster heart rates in pacemaker patients have not yet been shown. Intuitively, however, this would appear to be a desirable approach and will probably be added to the design of future generations of dual-chamber pacemakers. Studies of the effect of different pacing modes on secretion of atrial natriuretic factor are intriguing and may contribute more to our understanding of pacing hemodynamics in the future. During exercise, heart rate increase is more important than AV synchrony and this has been shown by several studies. Thus, in active patients with chronotropic incompetence due to sick sinus syndrome, the addition of rate-adaptive pacing is important. Because single-chamber rate-adaptive atrial pacing leaves the patient exposed to the risk of future development of AV block and DDD pacing does not provide chronotropic support, it is likely that the new rate-adaptive dual-chamber (DDDR) devices will be used in a significant number of these patients. Dual-chamber rate-adaptive pacemakers are now available to meet the clinical needs of such patients. Baseline left ventricular function as measured by ejection fraction does not appear to predict the relative benefit of rate-adaptive pacing. There are several studies on the effect of different pacing modes on coronary blood flow in patients with ischemic heart disease. The physiologic effects of different modes of pacing on coronary blood flow are complex. In general, dual-chamber pacing provides a higher cardiac output without disturbing myocardial oxygen balance if the upper-rate limit is appropriately controlled. The upper-rate limit can be arbitrarily set to less than 100 or to a value less than that associated with angina on a treadmil test. Future studies of differing pacing modes and settings in patients with other types of heart disease are needed. Studies have been performed on the chronic effects of differing pacing modes on exercise and hemodynamics and the results are very interesting. It appears that dual-chamber pacing may reduce heart size and has long-term beneficial effects on exercise ability. In the patient with preexisting congestive heart failure, dual-chamber pacing appears to improve survival compared with VVI pacing. Although the new features added to pacemakers in the past 10 years may improve physiology, they also increase the likelihood of malfunction, pseudomalfunction, and other complications. Studies show that most of the complications of dual-chamber pacing can be treated by reprogramming. However, this requires knowledgeable and careful pacemaker follow-up. In addition, a pacemaker patient's condition and underlying rhythm may change over time requiring adjustments in pacemaker program settings by the physician. Currently in the United States, less than a third of permanent pacemaker implants are dual-chamber devices whereas the newly introduced single-chamber rate-adaptive devices are implanted in 20% of patients. The reason for the lack of enthusiasm for dual-chamber pacing is that many physicians are uncomfortable with atrial lead positioning. The use of single-chamber atrial pacing in the United States is extremely low, although this approach has enjoyed popularity in Europe. 75 A committee from the North American Society of Pacing and Electrophysiology suggested that DDD pacemakers are indicated in 60% to 80% of all implants. 76 The data reviewed here support an increased use of dual-chamber pacing.

Development of a rate adaptive pacemaker based on the maximum rate-of-rise of right ventricular pressure (RV dP/dtmax).

The maximum rate of rise of right ventricular pressure (RV dP/dtmax) may change in response to physiological stress and thereby provide an appropriate parameter upon which to base rate adaptive pacing. Initial feasibility testing was carried out in six patients using externally closed loop rate adaptive pacing with a pressure sensing lead (Model 6220) and an investigational VVI pulse generator (Medtronic, Model 2451). During exercise, maximum positive RV dP/dtmax increased from 223 +/- 55 to 405 +/- 181 mmHg.sec.1 (P less than 0.05). Based on these results, rate adaptive pulse generators using maximum positive RV dP/dt were implanted in 12 patients (Medtronic, Model 2503). Exercise treadmill testing in the VVI mode resulted in heart rates ranging from 69 +/- 6 beats/min at rest to 79 +/- 14 beats/min (n = 12; P greater than 0.05). In contrast, VVIR mode pacing rates ranged from 71 +/- 11 beats/min to 115 +/- 24 beats/min (n = 17; P less than 0.05). Holter recording showed heart rates ranging from 51 +/- 6 to 110 +/- 22 beats/min during activities of normal daily living (n = 9; P less than 0.05). Passive postural tilt resulted in rates of 69 +/- 8 beats/min in the supine position increasing to 74 +/- 14 beats/min with 60 degrees upright tilt (n = 16; P greater than 0.05). With up to 5-year follow-up data, there have been no late failures of pacing but one lead showed insulation failure with over- and undersensing after 4.5 years. A number of deficiencies were identified in the prototypes leading to modifications of a subsequent generation of rate responsive pacemaker based on RV dP/dtmax. These initial data demonstrate that rate adaptive pacing based on RV dP/dtmax responds in a physiological manner. This rate responsive system is of particular interest as it is based on a beat-to-beat parameter of cardiac mechanical function.

First derivative of right ventricular pressure, dP/dt, as a sensor for a rate adaptive VVI pacemaker: initial experience.

Ten patients underwent implantation of a rate adaptive ventricular pacing system with a new pulse generator and lead. The unipolar lead has a steroid eluting tip and a pressure sensor. The first derivative of the signal from this sensor, dP/dt, is determined and the pacemaker rate is varied in response to changes in the right ventricular dP/dtMAX. During implantation, dP/dt values were in the range of 180-720 mm Hg/sec. The autothreshold for pacing at 2.5 V remained unchanged 1 month after implantation (0.065 +/- 0.045 msec, range 0.05-2.00 msec) and only slightly increased after 3 months (0.075 +/- 0.045 msec, range 0.05-2.00 msec). A significant correlation existed between the dP/dt measured during implantation and the right ventricular pressure measured by telemetry at follow-up visits (r = 0.93, P = 0.0001). Initial pacemaker programming was performed on the second day after implantation following a short walk and was adjusted subsequent to follow-up visits according to the patient's subjective assessment and in accordance with the results of exercise tests and Holter monitoring. Exercise and Holter tests did not significantly change initial programming. There was a significant correlation between right ventricular systolic pressure and the rate response setting (r = -0.66, P less than 0.05). During dP/dt pacing, all patients felt well, and eight of these reported an improvement compared to nonrate adaptive pacing. The heart rate response to effort and recovery was appropriate. It was concluded that: (1) right ventricular dP/dt is a suitable parameter for controlling the pacing rate; (2) appropriate programming of the dP/dt pacemaker results in a suitable heart rate response to exercise and recovery.

Limitations of testing methods for evaluation of dual chamber versus single chamber adaptive rate pacing

As new modes of cardiac pacing are developed, it is important to determine if these modes offer additional benefits over already existing options. Comparisons between dual (DDDR) and single chamber ventricular (VVIR) rate-modulated pacing using standard exercise protocols have produced conflicting results. 1–4 Exercise duration alone does not appear to accurately reflect differences in cardiac efficiency and tissue perfusion. Similarly, maximal oxygen uptake tends to reflect exercise duration rather than cardiac performance. 5 This study was designed to compare the DDDR and VVIR pacing modes using measures of exercise duration and maximal oxygen uptake, as well as less frequently used parameters, including anaerobic threshold time, maximal carbon dioxide production, respiratory exchange ratio, cardiac output, and the ratio of cardiac output to oxygen uptake.

Sensor for Right Ventricular Volumes Using the Trailing Edge Voltage of a Pulse Generator Output

Cardiac and thoracic volume (Vol) signals are useful for diagnosis and adaptive rate pacing. Present systems need an AC or pulsed constant current carrier to measure conductivity (proportional to Vol), causing high battery drain and requiring complex detection algorithms or special leads. The aim of this study was to propose a new and simple sensor for cardiac volumes using standard pacing leads and no AC carrier signal. "Constant voltage" pulse generators (PG) deliver a square pulse to the lead via a capacitor (Cap). The signal resulting from the interaction between the PG and the tissues and blood is trapezoidal, with a leading edge voltage determined by PG output and a trailing edge voltage (TEV) dependent on electrode surface and Cap value (device constants), and patient load. The hypothesis that right ventricular (RV) and chest Vol variations could produce load-related TEV changes was tested. Four PGs were connected to bipolar (Bip) leads within containers with 5-80 cc of saline, and TEV was measured with every 5 cc Vol change. Fifteen patients with previously implanted Bip PGs were studied during VOO pacing, scanning the intrinsic cardiac cycle. TEV was noninvasively measured as a function of time from onset of QRS.(ABSTRACT TRUNCATED AT 250 WORDS)